Consensus statement on the use of rituximab in patients with rheumatoid arthritis.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 17068064.
- Also identified by PMC identifier 1798500.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid